1
|
Gendron T, Lanfranchi DA, Wenzel NI, Kessedjian H, Jannack B, Maes L, Cojean S, Müller TJJ, Loiseau PM, Davioud-Charvet E. Chemoselective Synthesis and Anti-Kinetoplastidal Properties of 2,6-Diaryl-4 H-tetrahydro-thiopyran-4-one S-Oxides: Their Interplay in a Cascade of Redox Reactions from Diarylideneacetones. Molecules 2024; 29:1620. [PMID: 38611899 PMCID: PMC11013284 DOI: 10.3390/molecules29071620] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2024] [Revised: 03/26/2024] [Accepted: 04/01/2024] [Indexed: 04/14/2024] Open
Abstract
2,6-Diaryl-4H-tetrahydro-thiopyran-4-ones and corresponding sulfoxide and sulfone derivatives were designed to lower the major toxicity of their parent anti-kinetoplatidal diarylideneacetones through a prodrug effect. Novel diastereoselective methodologies were developed and generalized from diarylideneacetones and 2,6-diaryl-4H-tetrahydro-thiopyran-4-ones to allow the introduction of a wide substitution profile and to prepare the related S-oxides. The in vitro biological activity and selectivity of diarylideneacetones, 2,6-diaryl-4H-tetrahydro-thiopyran-4-ones, and their S-sulfoxide and sulfone metabolites were evaluated against Trypanosoma brucei brucei, Trypanosoma cruzi, and various Leishmania species in comparison with their cytotoxicity against human fibroblasts hMRC-5. The data revealed that the sulfides, sulfoxides, and sulfones, in which the Michael acceptor sites are temporarily masked, are less toxic against mammal cells while the anti-trypanosomal potency was maintained against T. b. brucei, T. cruzi, L. infantum, and L. donovani, thus confirming the validity of the prodrug strategy. The mechanism of action is proposed to be due to the involvement of diarylideneacetones in cascades of redox reactions involving the trypanothione system. After Michael addition of the dithiol to the double bonds, resulting in an elongated polymer, the latter-upon S-oxidation, followed by syn-eliminations-fragments, under continuous release of reactive oxygen species and sulfenic/sulfonic species, causing the death of the trypanosomal parasites in the micromolar or submicromolar range with high selectivity indexes.
Collapse
Affiliation(s)
- Thibault Gendron
- UMR7042 Université de Strasbourg–CNRS–UHA, Laboratoire d’Innovation Moléculaire et Applications (LIMA), Team Bio(IN)organic and Medicinal Chemistry, European School of Chemistry, Polymers and Materials (ECPM), 25 Rue Becquerel, F-67087 Strasbourg, France; (T.G.); (D.A.L.); (H.K.)
| | - Don Antoine Lanfranchi
- UMR7042 Université de Strasbourg–CNRS–UHA, Laboratoire d’Innovation Moléculaire et Applications (LIMA), Team Bio(IN)organic and Medicinal Chemistry, European School of Chemistry, Polymers and Materials (ECPM), 25 Rue Becquerel, F-67087 Strasbourg, France; (T.G.); (D.A.L.); (H.K.)
| | - Nicole I. Wenzel
- Bioorganic & Medicinal Chemistry Laboratory, Biochemie-Zentrum, Heidelberg University, Im Neuenheimer Feld 504, D-69120 Heidelberg, Germany; (N.I.W.)
| | - Hripsimée Kessedjian
- UMR7042 Université de Strasbourg–CNRS–UHA, Laboratoire d’Innovation Moléculaire et Applications (LIMA), Team Bio(IN)organic and Medicinal Chemistry, European School of Chemistry, Polymers and Materials (ECPM), 25 Rue Becquerel, F-67087 Strasbourg, France; (T.G.); (D.A.L.); (H.K.)
| | - Beate Jannack
- Bioorganic & Medicinal Chemistry Laboratory, Biochemie-Zentrum, Heidelberg University, Im Neuenheimer Feld 504, D-69120 Heidelberg, Germany; (N.I.W.)
| | - Louis Maes
- Laboratory of Microbiology, Parasitology and Hygiene (LMPH), Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Universiteitsplein 1, B-2610 Antwerp, Belgium;
| | - Sandrine Cojean
- Antiparasitic Chemotherapy, Faculty of Pharmacy, BioCIS, UMR 8076 Université Paris-Saclay-CNRS 17, Rue des Sciences, F-91400 Orsay, France; (S.C.); (P.M.L.)
| | - Thomas J. J. Müller
- Institut für Organische Chemie und Makromolekulare Chemie, Mathematisch-Naturwissenschaftliche FakultätFakultät, Heinrich-Heine-Universität Düsseldorf, Universitätsstraße 1, D-40225 Düsseldorf, Germany;
| | - Philippe M. Loiseau
- Antiparasitic Chemotherapy, Faculty of Pharmacy, BioCIS, UMR 8076 Université Paris-Saclay-CNRS 17, Rue des Sciences, F-91400 Orsay, France; (S.C.); (P.M.L.)
| | - Elisabeth Davioud-Charvet
- UMR7042 Université de Strasbourg–CNRS–UHA, Laboratoire d’Innovation Moléculaire et Applications (LIMA), Team Bio(IN)organic and Medicinal Chemistry, European School of Chemistry, Polymers and Materials (ECPM), 25 Rue Becquerel, F-67087 Strasbourg, France; (T.G.); (D.A.L.); (H.K.)
| |
Collapse
|
2
|
Beltran-Hortelano I, Atherton RL, Rubio-Hernández M, Sanz-Serrano J, Alcolea V, Kelly JM, Pérez-Silanes S, Olmo F. Design and synthesis of Mannich base-type derivatives containing imidazole and benzimidazole as lead compounds for drug discovery in Chagas Disease. Eur J Med Chem 2021; 223:113646. [PMID: 34182359 DOI: 10.1016/j.ejmech.2021.113646] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2021] [Revised: 06/09/2021] [Accepted: 06/10/2021] [Indexed: 10/21/2022]
Abstract
The protozoan parasite Trypanosoma cruzi is the causative agent of Chagas disease, the most important parasitic infection in Latin America. The only treatments currently available are nitro-derivative drugs that are characterised by high toxicity and limited efficacy. Therefore, there is an urgent need for more effective, less toxic therapeutic agents. We have previously identified the potential for Mannich base derivatives as novel inhibitors of this parasite. To further explore this family of compounds, we synthesised a panel of 69 new analogues, based on multi-parametric structure-activity relationships, which allowed optimization of both anti-parasitic activity, physicochemical parameters and ADME properties. Additionally, we optimized our in vitro screening approaches against all three developmental forms of the parasite, allowing us to discard the least effective and trypanostatic derivatives at an early stage. We ultimately identified derivative 3c, which demonstrated excellent trypanocidal properties, and a synergistic mode of action against trypomastigotes in combination with the reference drug benznidazole. Both its druggability and low-cost production make this derivative a promising candidate for the preclinical, in vivo assays of the Chagas disease drug-discovery pipeline.
Collapse
Affiliation(s)
- Iván Beltran-Hortelano
- Universidad de Navarra, ISTUN Instituto de Salud Tropical, Irunlarrea 1, 31008, Pamplona, Spain; Universidad de Navarra, Pharmacy and Nutrition Faculty, Department of Pharmaceutical Technology and Chemistry, Campus Universitario, 31080, Pamplona, Spain
| | - Richard L Atherton
- Department of Infection Biology, London School of Hygiene and Tropical Medicine, London, WC1 7HT, United Kingdom
| | - Mercedes Rubio-Hernández
- Universidad de Navarra, ISTUN Instituto de Salud Tropical, Irunlarrea 1, 31008, Pamplona, Spain; Universidad de Navarra, Pharmacy and Nutrition Faculty, Department of Pharmaceutical Technology and Chemistry, Campus Universitario, 31080, Pamplona, Spain
| | - Julen Sanz-Serrano
- Universidad de Navarra, Pharmacy and Nutrition Faculty, Department of Pharmacology and Toxicology, Irunlarrea 1, 31008, Pamplona, Spain
| | - Verónica Alcolea
- Universidad de Navarra, ISTUN Instituto de Salud Tropical, Irunlarrea 1, 31008, Pamplona, Spain; Universidad de Navarra, Pharmacy and Nutrition Faculty, Department of Pharmaceutical Technology and Chemistry, Campus Universitario, 31080, Pamplona, Spain
| | - John M Kelly
- Department of Infection Biology, London School of Hygiene and Tropical Medicine, London, WC1 7HT, United Kingdom
| | - Silvia Pérez-Silanes
- Universidad de Navarra, ISTUN Instituto de Salud Tropical, Irunlarrea 1, 31008, Pamplona, Spain; Universidad de Navarra, Pharmacy and Nutrition Faculty, Department of Pharmaceutical Technology and Chemistry, Campus Universitario, 31080, Pamplona, Spain.
| | - Francisco Olmo
- Department of Infection Biology, London School of Hygiene and Tropical Medicine, London, WC1 7HT, United Kingdom.
| |
Collapse
|
3
|
Silva DG, Junker A, de Melo SMG, Fumagalli F, Gillespie JR, Molasky N, Buckner FS, Matheeussen A, Caljon G, Maes L, Emery FS. Synthesis and Structure-Activity Relationships of Imidazopyridine/Pyrimidine- and Furopyridine-Based Anti-infective Agents against Trypanosomiases. ChemMedChem 2020; 16:966-975. [PMID: 33078573 PMCID: PMC8048860 DOI: 10.1002/cmdc.202000616] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/13/2020] [Revised: 10/13/2020] [Indexed: 12/22/2022]
Abstract
Neglected tropical diseases remain among the most critical public health concerns in Africa and South America. The drug treatments for these diseases are limited, which invariably leads to fatal cases. Hence, there is an urgent need for new antitrypanosomal drugs. To address this issue, a large number of diverse heterocyclic compounds were prepared. Straightforward synthetic approaches tolerated pre-functionalized structures, giving rise to a structurally diverse set of analogs. We report on a set of 57 heterocyclic compounds with selective activity potential against kinetoplastid parasites. In general, 29 and 19 compounds of the total set could be defined as active against Trypanosoma cruzi and T. brucei brucei, respectively (antitrypanosomal activities <10 μM). The present work discusses the structure-activity relationships of new fused-ring scaffolds based on imidazopyridine/pyrimidine and furopyridine cores. This library of compounds shows significant potential for anti-trypanosomiases drug discovery.
Collapse
Affiliation(s)
- Daniel G Silva
- QHeteM - Laboratório de Química Heterocíclica e Medicinal, School of Pharmaceutical Sciences of Ribeirão Preto - University of São Paulo, Ribeirão Preto, São Paulo, 14040-903, Brazil.,European Institute for Molecular Imaging (EIMI), Westphalian Wilhelms-University, 48149, Münster, Germany
| | - Anna Junker
- European Institute for Molecular Imaging (EIMI), Westphalian Wilhelms-University, 48149, Münster, Germany
| | - Shaiani M G de Melo
- QHeteM - Laboratório de Química Heterocíclica e Medicinal, School of Pharmaceutical Sciences of Ribeirão Preto - University of São Paulo, Ribeirão Preto, São Paulo, 14040-903, Brazil
| | - Fernando Fumagalli
- Centro de Ciências da Saúde (CCS), Universidade Federal de Santa Maria (UFSM), Av. Roraima, 1000, Camobi, Santa Maria, Rio Grande do Sul, 97105-900, Brazil
| | - J Robert Gillespie
- Department of Medicine, University of Washington, Seattle, WA, 98195, USA
| | - Nora Molasky
- Department of Medicine, University of Washington, Seattle, WA, 98195, USA
| | | | - An Matheeussen
- Laboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Universiteitsplein 1, Antwerpen, 2610, Wilrijk, Belgium
| | - Guy Caljon
- Laboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Universiteitsplein 1, Antwerpen, 2610, Wilrijk, Belgium
| | - Louis Maes
- Laboratory of Microbiology, Parasitology and Hygiene (LMPH), University of Antwerp, Universiteitsplein 1, Antwerpen, 2610, Wilrijk, Belgium
| | - Flavio S Emery
- QHeteM - Laboratório de Química Heterocíclica e Medicinal, School of Pharmaceutical Sciences of Ribeirão Preto - University of São Paulo, Ribeirão Preto, São Paulo, 14040-903, Brazil
| |
Collapse
|
4
|
Paucar R, Martín-Escolano R, Moreno-Viguri E, Azqueta A, Cirauqui N, Marín C, Sánchez-Moreno M, Pérez-Silanes S. Rational modification of Mannich base-type derivatives as novel antichagasic compounds: Synthesis, in vitro and in vivo evaluation. Bioorg Med Chem 2019; 27:3902-3917. [DOI: 10.1016/j.bmc.2019.07.029] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/02/2019] [Revised: 07/10/2019] [Accepted: 07/17/2019] [Indexed: 12/17/2022]
|
5
|
Paucar R, Martín‐Escolano R, Moreno‐Viguri E, Cirauqui N, Marín C, Sánchez‐Moreno M, Pérez‐Silanes S. Antichagasic profile of a Series of Mannich Base‐Type Derivatives: Design, Synthesis,
in vitro
Evaluation, and Computational Studies Involving Iron Superoxide Dismutase. ChemistrySelect 2019. [DOI: 10.1002/slct.201901108] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- Rocío Paucar
- Universidad de NavarraDepartment of Pharmaceutical Technology and ChemistryInstituto de Salud Tropical Pamplona 31008 Spain
| | - Rubén Martín‐Escolano
- Department of ParasitologyInstituto de Investigación Biosanitaria (ibs. Granada)Hospitales Universitarios de Granada/University of Granada, Severo Ochoa s/n, E-18071, Granada Spain
| | - Elsa Moreno‐Viguri
- Universidad de NavarraDepartment of Pharmaceutical Technology and ChemistryInstituto de Salud Tropical Pamplona 31008 Spain
| | - Nuria Cirauqui
- Department of Pharmaceutical SciencesFederal University of Rio de Janeiro Rio de Janeiro 21949–900 Brazil
| | - Clotilde Marín
- Department of ParasitologyInstituto de Investigación Biosanitaria (ibs. Granada)Hospitales Universitarios de Granada/University of Granada, Severo Ochoa s/n, E-18071, Granada Spain
| | - Manuel Sánchez‐Moreno
- Department of ParasitologyInstituto de Investigación Biosanitaria (ibs. Granada)Hospitales Universitarios de Granada/University of Granada, Severo Ochoa s/n, E-18071, Granada Spain
| | - Silvia Pérez‐Silanes
- Universidad de NavarraDepartment of Pharmaceutical Technology and ChemistryInstituto de Salud Tropical Pamplona 31008 Spain
| |
Collapse
|
6
|
Paucar R, Martín-Escolano R, Moreno-Viguri E, Cirauqui N, Rodrigues CR, Marín C, Sánchez-Moreno M, Pérez-Silanes S, Ravera M, Gabano E. A step towards development of promising trypanocidal agents: Synthesis, characterization and in vitro biological evaluation of ferrocenyl Mannich base-type derivatives. Eur J Med Chem 2019; 163:569-582. [DOI: 10.1016/j.ejmech.2018.12.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2018] [Revised: 11/29/2018] [Accepted: 12/02/2018] [Indexed: 02/06/2023]
|
7
|
Martín-Escolano R, Moreno-Viguri E, Santivañez-Veliz M, Martin-Montes A, Medina-Carmona E, Paucar R, Marín C, Azqueta A, Cirauqui N, Pey AL, Pérez-Silanes S, Sánchez-Moreno M. Second Generation of Mannich Base-Type Derivatives with in Vivo Activity against Trypanosoma cruzi. J Med Chem 2018; 61:5643-5663. [PMID: 29883536 DOI: 10.1021/acs.jmedchem.8b00468] [Citation(s) in RCA: 25] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
Chagas disease is a potentially life-threatening and neglected tropical disease caused by Trypanosoma cruzi. One of the most important challenges related to Chagas disease is the search for new, safe, effective, and affordable drugs since the current therapeutic arsenal is inadequate and insufficient. Here, we report a simple and cost-effective synthesis and the biological evaluation of the second generation of Mannich base-type derivatives. Compounds 7, 9, and 10 showed improved in vitro efficiency and lower toxicity than benznidazole, in addition to no genotoxicity; thus, they were applied in in vivo assays to assess their activity in both acute and chronic phases of the disease. Compound 10 presented a similar profile to benznidazole from the parasitological perspective but also yielded encouraging data, as no toxicity was observed. Moreover, compound 9 showed lower parasitaemia and higher curative rates than benznidazole, also with lower toxicity in both acute and chronic phases. Therefore, further studies should be considered to optimize compound 9 to promote its further preclinical evaluation.
Collapse
Affiliation(s)
- Rubén Martín-Escolano
- Departament of Parasitology , Instituto de Investigación Biosanitaria (ibs.Granada), Hospitales Universitarios De Granada/University of Granada , Severo Ochoa s/n , E-18071 Granada , Spain
| | - Elsa Moreno-Viguri
- Universidad de Navarra , Department of Organic and Pharmaceutical Chemistry, Instituto de Salud Tropical , Pamplona 31008 , Spain
| | - Mery Santivañez-Veliz
- Universidad de Navarra , Department of Organic and Pharmaceutical Chemistry, Instituto de Salud Tropical , Pamplona 31008 , Spain
| | - Alvaro Martin-Montes
- Departament of Parasitology , Instituto de Investigación Biosanitaria (ibs.Granada), Hospitales Universitarios De Granada/University of Granada , Severo Ochoa s/n , E-18071 Granada , Spain
| | - Encarnación Medina-Carmona
- Department of Physical Chemistry, Faculty of Sciences , University of Granada , Av. Fuentenueva s/n , 18071 Granada , Spain
| | - Rocío Paucar
- Universidad de Navarra , Department of Organic and Pharmaceutical Chemistry, Instituto de Salud Tropical , Pamplona 31008 , Spain
| | - Clotilde Marín
- Departament of Parasitology , Instituto de Investigación Biosanitaria (ibs.Granada), Hospitales Universitarios De Granada/University of Granada , Severo Ochoa s/n , E-18071 Granada , Spain
| | - Amaya Azqueta
- Universidad de Navarra , Department of Pharmacology and Toxicology , Pamplona 31008 , Spain
| | - Nuria Cirauqui
- Department of Pharmaceutical Sciences , Federal University of Rio de Janeiro , Rio de Janeiro 21949-900 , Brazil
| | - Angel L Pey
- Department of Physical Chemistry, Faculty of Sciences , University of Granada , Av. Fuentenueva s/n , 18071 Granada , Spain
| | - Silvia Pérez-Silanes
- Universidad de Navarra , Department of Organic and Pharmaceutical Chemistry, Instituto de Salud Tropical , Pamplona 31008 , Spain
| | - Manuel Sánchez-Moreno
- Departament of Parasitology , Instituto de Investigación Biosanitaria (ibs.Granada), Hospitales Universitarios De Granada/University of Granada , Severo Ochoa s/n , E-18071 Granada , Spain
| |
Collapse
|
8
|
In vitro antileishmanial activity and iron superoxide dismutase inhibition of arylamine Mannich base derivatives. Parasitology 2017; 144:1783-1790. [PMID: 28789716 DOI: 10.1017/s0031182017001123] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Leishmaniasis is one of the world's most neglected diseases, and it has a worldwide prevalence of 12 million. There are no effective human vaccines for its prevention, and treatment is hampered by outdated drugs. Therefore, research aiming at the development of new therapeutic tools to fight leishmaniasis remains a crucial goal today. With this purpose in mind, we present 20 arylaminoketone derivatives with a very interesting in vitro and in vivo efficacy against Trypanosoma cruzi that have now been studied against promastigote and amastigote forms of Leishmania infantum, Leishmania donovani and Leishmania braziliensis strains. Six out of the 20 Mannich base-type derivatives showed Selectivity Index between 39 and 2337 times higher in the amastigote form than the reference drug glucantime. These six derivatives affected the parasite infectivity rates; the result was lower parasite infectivity rates than glucantime tested at an IC25 dose. In addition, these derivatives were substantially more active against the three Leishmania species tested than glucantime. The mechanism of action of these compounds has been studied, showing a greater alteration in glucose catabolism and leading to greater levels of iron superoxide dismutase inhibition. These molecules could be potential candidates for leishmaniasis chemotherapy.
Collapse
|
9
|
In Silico Mining for Antimalarial Structure-Activity Knowledge and Discovery of Novel Antimalarial Curcuminoids. Molecules 2016; 21:molecules21070853. [PMID: 27367660 PMCID: PMC6273176 DOI: 10.3390/molecules21070853] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/01/2016] [Revised: 06/04/2016] [Accepted: 06/10/2016] [Indexed: 11/17/2022] Open
Abstract
Malaria is a parasitic tropical disease that kills around 600,000 patients every year. The emergence of resistant Plasmodium falciparum parasites to artemisinin-based combination therapies (ACTs) represents a significant public health threat, indicating the urgent need for new effective compounds to reverse ACT resistance and cure the disease. For this, extensive curation and homogenization of experimental anti-Plasmodium screening data from both in-house and ChEMBL sources were conducted. As a result, a coherent strategy was established that allowed compiling coherent training sets that associate compound structures to the respective antimalarial activity measurements. Seventeen of these training sets led to the successful generation of classification models discriminating whether a compound has a significant probability to be active under the specific conditions of the antimalarial test associated with each set. These models were used in consensus prediction of the most likely active from a series of curcuminoids available in-house. Positive predictions together with a few predicted as inactive were then submitted to experimental in vitro antimalarial testing. A large majority from predicted compounds showed antimalarial activity, but not those predicted as inactive, thus experimentally validating the in silico screening approach. The herein proposed consensus machine learning approach showed its potential to reduce the cost and duration of antimalarial drug discovery.
Collapse
|
10
|
Roman G. Mannich bases in medicinal chemistry and drug design. Eur J Med Chem 2015; 89:743-816. [PMID: 25462280 PMCID: PMC7115492 DOI: 10.1016/j.ejmech.2014.10.076] [Citation(s) in RCA: 190] [Impact Index Per Article: 21.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2014] [Revised: 10/22/2014] [Accepted: 10/23/2014] [Indexed: 01/18/2023]
Abstract
The biological activity of Mannich bases, a structurally heterogeneous class of chemical compounds that are generated from various substrates through the introduction of an aminomethyl function by means of the Mannich reaction, is surveyed, with emphasis on the relationship between structure and biological activity. The review covers extensively the literature reports that have disclosed Mannich bases as anticancer and cytotoxic agents, or compounds with potential antibacterial and antifungal activity in the last decade. The most relevant studies on the activity of Mannich bases as antimycobacterial agents, antimalarials, or antiviral candidates have been included as well. The review contains also a thorough coverage of anticonvulsant, anti-inflammatory, analgesic and antioxidant activities of Mannich bases. In addition, several minor biological activities of Mannich bases, such as their ability to regulate blood pressure or inhibit platelet aggregation, their antiparasitic and anti-ulcer effects, as well as their use as agents for the treatment of mental disorders have been presented. The review gives in the end a brief overview of the potential of Mannich bases as inhibitors of various enzymes or ligands for several receptors.
Collapse
Affiliation(s)
- Gheorghe Roman
- Petru Poni Institute of Macromolecular Chemistry, Department of Inorganic Polymers, 41A Aleea Gr. Ghica Vodă, Iaşi 700487, Romania.
| |
Collapse
|
11
|
Venkatraj M, Ariën KK, Heeres J, Joossens J, Dirié B, Lyssens S, Michiels J, Cos P, Lewi PJ, Vanham G, Maes L, Van der Veken P, Augustyns K. From human immunodeficiency virus non-nucleoside reverse transcriptase inhibitors to potent and selective antitrypanosomal compounds. Bioorg Med Chem 2014; 22:5241-8. [DOI: 10.1016/j.bmc.2014.08.005] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2014] [Revised: 08/06/2014] [Accepted: 08/07/2014] [Indexed: 01/11/2023]
|
12
|
Prati F, Goldman-Pinkovich A, Lizzi F, Belluti F, Koren R, Zilberstein D, Bolognesi ML. Quinone-amino acid conjugates targeting Leishmania amino acid transporters. PLoS One 2014; 9:e107994. [PMID: 25254495 PMCID: PMC4177859 DOI: 10.1371/journal.pone.0107994] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2014] [Accepted: 08/22/2014] [Indexed: 01/23/2023] Open
Abstract
The aim of the present study was to investigate the feasibility of targeting Leishmania transporters via appropriately designed chemical probes. Leishmania donovani, the parasite that causes visceral leishmaniasis, is auxotrophic for arginine and lysine and has specific transporters (LdAAP3 and LdAAP7) to import these nutrients. Probes 1–15 were originated by conjugating cytotoxic quinone fragments (II and III) with amino acids (i.e. arginine and lysine) by means of an amide linkage. The toxicity of the synthesized conjugates against Leishmania extracellular (promastigotes) and intracellular (amastigotes) forms was investigated, as well their inhibition of the relevant amino acid transporters. We observed that some conjugates indeed displayed toxicity against the parasites; in particular, 7 was identified as the most potent derivative (at concentrations of 1 µg/mL and 2.5 µg/mL residual cell viability was reduced to 15% and 48% in promastigotes and amastigotes, respectively). Notably, 6, while retaining the cytotoxic activity of quinone II, displayed no toxicity against mammalian THP1 cells. Transport assays indicated that the novel conjugates inhibited transport activity of lysine, arginine and proline transporters. Furthermore, our analyses suggested that the toxic conjugates might be translocated by the transporters into the cells. The non-toxic probes that inhibited transport competed with the natural substrates for binding to the transporters without being translocated. Thus, it is likely that 6, by exploiting amino acid transporters, can selectively deliver its toxic effects to Leishmania cells. This work provides the first evidence that amino acid transporters of the human pathogen Leishmania might be modulated by small molecules, and warrants their further investigation from drug discovery and chemical biology perspectives.
Collapse
Affiliation(s)
- Federica Prati
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum University of Bologna, Bologna, Italy
| | | | - Federica Lizzi
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum University of Bologna, Bologna, Italy
| | - Federica Belluti
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum University of Bologna, Bologna, Italy
| | - Roni Koren
- Faculty of Biology, Technion-Israel Institute of Technology, Haifa, Israel
| | - Dan Zilberstein
- Faculty of Biology, Technion-Israel Institute of Technology, Haifa, Israel
| | - Maria Laura Bolognesi
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum University of Bologna, Bologna, Italy
- * E-mail:
| |
Collapse
|
13
|
Toro MA, Sánchez-Murcia PA, Moreno D, Ruiz-Santaquiteria M, Alzate JF, Negri A, Camarasa MJ, Gago F, Velázquez S, Jiménez-Ruiz A. Probing the dimerization interface of Leishmania infantum trypanothione reductase with site-directed mutagenesis and short peptides. Chembiochem 2013; 14:1212-7. [PMID: 23744811 DOI: 10.1002/cbic.201200744] [Citation(s) in RCA: 21] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2012] [Revised: 03/22/2013] [Indexed: 11/07/2022]
Abstract
Binding at the interface: We tested the inhibitory activity of a set of peptide sequences derived from an α-helix of the dimeric trypanothione reductase from Leishmania infantum. Replacement of a glutamic acid residue with a lysine promoted monomer dissociation and enzyme inhibition.
Collapse
Affiliation(s)
- Miguel A Toro
- Departamento de Biología de Sistemas, Unidad Asociada de I+D+I al CSIC, Universidad de Alcalá, 28871 Alcalá de Henares, Madrid, Spain
| | | | | | | | | | | | | | | | | | | |
Collapse
|
14
|
Jacobs RT, Nare B, Phillips MA. State of the art in African trypanosome drug discovery. Curr Top Med Chem 2011; 11:1255-74. [PMID: 21401507 PMCID: PMC3101707 DOI: 10.2174/156802611795429167] [Citation(s) in RCA: 104] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2010] [Accepted: 11/25/2010] [Indexed: 11/22/2022]
Abstract
African sleeping sickness is endemic in sub-Saharan Africa where the WHO estimates that 60 million people are at risk for the disease. Human African trypanosomiasis (HAT) is 100% fatal if untreated and the current drug therapies have significant limitations due to toxicity and difficult treatment regimes. No new chemical agents have been approved since eflornithine in 1990. The pentamidine analog DB289, which was in late stage clinical trials for the treatment of early stage HAT recently failed due to toxicity issues. A new protocol for the treatment of late-stage T. brucei gambiense that uses combination nifurtomox/eflornithine (NECT) was recently shown to have better safety and efficacy than eflornithine alone, while being easier to administer. This breakthrough represents the only new therapy for HAT since the approval of eflornithine. A number of research programs are on going to exploit the unusual biochemical pathways in the parasite to identify new targets for target based drug discovery programs. HTS efforts are also underway to discover new chemical entities through whole organism screening approaches. A number of inhibitors with anti-trypanosomal activity have been identified by both approaches, but none of the programs are yet at the stage of identifying a preclinical candidate. This dire situation underscores the need for continued effort to identify new chemical agents for the treatment of HAT.
Collapse
Affiliation(s)
- Robert T. Jacobs
- SCYNEXIS, Inc., Research Triangle Park, North Carolina 27709-2878
| | - Bakela Nare
- SCYNEXIS, Inc., Research Triangle Park, North Carolina 27709-2878
| | - Margaret A. Phillips
- Department of Pharmacology, University of Texas Southwestern Medical Center at Dallas, 6001 Forest Park Rd, Dallas, Texas 75390-9041
| |
Collapse
|